Longest lesion length indication (up to 240 mm)
Unique helical design
Engineered for bending, compression, torsion
Dynamic vessel conformability
Improved lesion coverage with a single stent
A single-arm, prospective, non-randomized, multi-center study evaluating the safety and
effectiveness of the LIFESTENT® SOLO™ in the treatment of symptomatic vascular disease of the
SFA and/or proximal popliteal artery. Subjects were treated with conventional PTA followed by
implantation of the Bard LIFESTENT® Vascular Stent.
Q 76 patients
Q 7 study sites in Germany
Q Symptomatic de-novo or restenosed lesions
Q Average lesion length of 91 mm
*The LIFESTENT® Vascular Stent System and the LIFESTENT® SOLO™ Vascular Stent System are intended to improve luminal diameter in the treatment of symptomatic de-novo or
restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0-6.5 mm. †
The LIFESTENT® 5 mm diameter was not included in the LIFESTENT® 200 mm Trial.